Abcam, ab240019, Anti-Myf5 antibody [EPR4899] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MYF5 antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR4899,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab240019 is the carrier-free version of
ab125078
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Myf5 also known as Myogenic Factor 5 is a member of the myogenic regulatory factor (MRF) family. It plays a critical role in muscle differentiation. Myf5 has a molecular mass of approximately 29 kDa. It is expressed predominantly in skeletal muscle tissues. The protein is observed early in muscle development marking the beginning stages where muscle precursor cells commit to becoming muscle cells.
Biological function summary
Myf5 functions as a transcription factor that initiates muscle differentiation. It acts as part of a larger complex interacting with other MRFs such as MyoD and MYF6. These factors together regulate the expression of genes necessary for myoblasts to develop into mature muscle fibers. Myf5 directly binds to the promoter regions of target genes initiating transcription that supports muscle cell lineage progression.
Pathways
The myogenesis pathway is heavily influenced by Myf5 activity. It works in tandem with MyoD in the early specification of myoblasts and their proliferation. Secondary to this Myf5 forms a feedback loop with proteins like MEF2 and Pax7 which reinforces muscle identity. Myf5 expression helps maintain the balance between myoblast proliferation and differentiation ensuring effective muscle regeneration and repair.
Muscular dystrophy exemplifies a condition closely associated with Myf5. The protein's expression levels and functionality often correlate with the disease affecting muscle development and integrity. Satellite cells which express Myf5 become important in muscle repair and dysfunctional Myf5 can contribute to disease progression. Another disorder influenced by Myf5 is rhabdomyosarcoma where aberrant expression disrupts normal myogenic regulatory pathways alongside MyoD dysregulation potentially leading to tumorigenesis.